Articles

Results 1 to 5 of 6
Most popular |Most recent


In brief: anticompetitive agreements in the pharmaceutical sector in China

China - June 30 2020 The essential legal considerations surrounding anticompetitive agreements in the pharmaceutical sector in China, including the assessment framework and special issues with vertical agreements.

Hong (Cathryn) Jin, Yingling Wei.

Snapshot: anticompetitive unilateral conduct in the pharmaceutical sector in China

China - June 30 2020 A look at key practical considerations surrounding abuse of dominance and other anticompetitive unilateral conduct in the pharmaceutical sector in China, including IP rights abuse and pricing conduct.

Hong (Cathryn) Jin, Yingling Wei.

At a glance: pharmaceutical merger review in China

China - June 30 2020 This article looks at some of the key legal and practical issues surrounding the competition authorities' review of mergers in the pharmaceutical sector in China, including review triggers and thresholds.

Hong (Cathryn) Jin, Yingling Wei.

Pharmaceutical antitrust law in China

China - September 6 2019 A structured guide to antitrust law in the pharmaceutical sector in China, including the legislative and regulatory framework, merger review, anticompetitive agreements and abuse of dominance.

Hong (Cathryn) Jin, Yingling Wei.

Anticompetitive unilateral conduct in the pharmaceutical sector in China

China - September 6 2019 An overview of practical considerations surrounding abuse of dominance and other anticompetitive unilateral conduct in the pharmaceutical sector in China, including IP rights abuse and pricing conduct.

Hong (Cathryn) Jin, Yingling Wei.